Antithrombotic Therapy Duration after Patent Foramen Ovale Closure for Stroke Prevention: Impact on Long-Term Outcome

Table 3

Follow-up after PFO closure.

Characteristic		Before PS matching				After PS matching
		All	Gr short	Gr long		Gr short	Gr long
		N = 259	N = 88	N = 171	value	N = 86	N = 86	value
Duration of antithrombotic therapy (days)	median [IQR]	587 [194–2856]	184 [181–194]	1519 [594–3987]	<0.001	184 [181–194]	2390 [702–4172]	<0.001
Duration of aspirin	median [IQR]	630 [194–2315]	184 [181–194]	1324 [623–3007]		184 [181–194]	2125 [692–3307]
Duration of clopidogrel	median [IQR]	434 [222–837]	184	635 [381–2372]		184	529 [376–683]
Duration of dual antiplatelet therapy	median [IQR]	370 [194–4330]	184 [180–197]	4036 [496–5322]		184 [180–199]	4238 [858–5399]
Duration of anticoagulants	median [IQR]	185	185	—		185	—
Duration of aspirin + anticoagulants	median [IQR]	3711 [2221–5201]	—	3711 [2221–5201]		—	3711 [2221–5201]
Duration of follow-up (years)	median [IQR]	10 [4–13]	10 [4–14]	9 [3–13]	0.52	10 [4–14]	11 [6–14]	0.16
Major adverse events
Death	n (%)	4 (1.5)	0 (0)	4 (2.3)	0.15	0 (0)	1 (1)	0.32
Cardiovascular death	n (%)	1 (0.4)	0 (0)	1 (0.6)	1.00	0 (0)	0 (0)	—
Stroke	n (%)	7 (3)	2 (3)	5 (3)	0.83	2 (2)	3 (3)	1.00
Ischemic stroke	n (%)	8 (3)	3 (3)	5 (3)	0.83	3 (3)	3 (3)	1.00
Hemorrhagic stroke	n (%)	0 (0)	0 (0)	0 (0)	—	0 (0)	0 (0)	—
Cryptogenic stroke	n (%)	4 (2)	1 (1)	3 (2)	0.70	1 (1)	2 (2)	0.56
Major bleeding	n (%)	0 (0)	0 (0)	0 (0)	—	0 (0)	0 (0)	—
Other adverse events
Minor bleeding	n (%)	48 (19)	13 (15)	35 (20)	0.27	12 (14)	19 (22)	0.17
BARC-1	n (%)	44 (17)	12 (14)	32 (19)	0.38	11 (13)	16 (19)	0.40
BARC-2	n (%)	4 (2)	1 (1)	3 (2)	1.00	1 (1)	3 (3)	0.62
Transient ischemic attack	n (%)	9 (3)	3 (3)	6 (4)	1.00	3 (3)	3 (3)	1.00
Atrial fibrillation (paroxysmal)	n (%)	17 (7)	3 (3)	14 (8)	0.18	3 (3)	7 (8)	0.33

Gr = Group; IQR = interquartile range; PS = propensity score.